Recon: FDA grants priority review for Biogen-Eisai’s Alzheimer’s drug; Senate Democrats advance drug-price deal

ReconReconBiologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy